Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03415854 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
A Phase 2 study, sponsored by HonorHealth Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03415854: Completed Phase 2 study, sponsored by HonorHealth Research Institute.
NCT03415854 is a Phase 2 study that has completed, run by HonorHealth Research Institute. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03415854, a Phase 2 study, has completed, sponsored by HonorHealth Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
Primary Outcome
Best overall response (BOR) is defined as the best tumor response recorded 9 weeks after treatment initiation Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1). Responses are categorized as: complete response (CR), disappearance of all target lesions; partial response (PR), ≥30% decrease in the sum of the longest diameter of target lesions; stable disease (SD), no change in target lesion size; and progressive disease (PD), ≥20% increase in the sum of the longest diameter of
Interventions
- DRUG Paricalcitol (Zemplar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2023-12-11 |
| Phase | Phase 2 |
What the finished NCT03415854 record still lists
NCT03415854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Paricalcitol (Zemplar) is the first listed.
NCT03415854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03415854 about?
NCT03415854 is a clinical study titled "Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)". The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with previously untreated metastatic pancreatic cancer.
What is the current status of trial NCT03415854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-01-31. Estimated completion is 2023-12-11.
What interventions are being tested in trial NCT03415854?
The interventions under investigation include: Paricalcitol (Zemplar) (DRUG).
Who is sponsoring clinical trial NCT03415854?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03415854's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI